Enzymatic characterization of the Plasmodium vivax chitinase, a potential malaria transmission-blocking target

被引:24
|
作者
Takeo, Satoru [1 ]
Hisamori, Daisuke [1 ]
Matsuda, Shusaku [1 ]
Vinetz, Joseph [2 ]
Sattabongkot, Jetsumon [3 ]
Tsuboi, Takafumi [1 ,4 ]
机构
[1] Ehime Univ, Cell Free Sci & Technol Res Ctr, Matsuyama, Ehime 7908577, Japan
[2] Univ Calif San Diego, Sch Med, Div Infect Dis, Palade Labs 0741, La Jolla, CA 92093 USA
[3] Armed Forces Res Inst Med Sci, Dept Entomol, Bangkok 10400, Thailand
[4] Ehime Univ, Venture Business Lab, Matsuyama, Ehime 7908577, Japan
基金
美国国家卫生研究院;
关键词
Chitinase; Transmission-blocking; Plasmodium vivax; Allosamidin; PROTEIN-SYNTHESIS SYSTEM; PARASITE CHITINASE; MOSQUITO MIDGUT; FALCIPARUM CHITINASE; VACCINE CANDIDATES; GALLINACEUM; ANTIBODY; INVASION; ENZYMES; PFCHT1;
D O I
10.1016/j.parint.2009.05.002
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
The chitinase (EC 3.2.1.14) of the human malaria parasite Plasmodium falciparum, PfCHT1, has been validated as a malaria transmission-blocking vaccine (TBV). The present study aimed to delineate functional characteristics of the P. vivax chitinase PvCHT1, whose primary structure differs from that of PfCHT1 by having proenzyme and chitin-binding domains. The recombinant protein rPvCHT1 expressed with a wheat germ cell-free system hydrolyzed 4-methylumbelliferone (4MU) derivatives of chitin oligosaccharides (beta-1,4-poly-N-acetyl glucosamine (GlcNAc)). An anti-rPvCHT1 polyclonal antiserum reacted with in vitro obtained P. vivax ookinetes in anterior cytoplasm, showing uneven patchy distribution. Enzymatic activity of rPvCHT1 shared the exclusive endochitinase property with parallelly expressed rPfCHT1 as demonstrated by a marked substrate preference for 4MU-GlcNAc(3) compared to shorter GlcNAc substrates. While rPvCHT1 was found to be sensitive to the general family-18 chitinase inhibitor, allosamidin, its pH (maximal in neutral environment) and temperature (max. at similar to 25 degrees C) activity profiles and sensitivity to allosamidin (IC50 = 6 mu M) were different from rPfCHT1. The results in this first report of functional rPvCHT1 synthesis indicate that the P. vivax chitinase is enzymatically close to long form Plasmodium chitinases represented by P. gallinaceum PgCHT1. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:243 / 248
页数:6
相关论文
共 50 条
  • [41] Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine
    Miyata, Takeshi
    Harakuni, Tetsuya
    Sugawa, Hideki
    Sattabongkot, Jetsumon
    Kato, Aki
    Tachibana, Mayumi
    Torii, Motomi
    Tsuboi, Takafumi
    Arakawa, Takeshi
    VACCINE, 2011, 29 (15) : 2720 - 2726
  • [42] Transmission-blocking drugs for malaria elimination
    Birkholtz, Lyn-Marie
    Alano, Pietro
    Leroy, Didier
    TRENDS IN PARASITOLOGY, 2022, 38 (05) : 390 - 403
  • [43] Apical Surface Expression of Aspartic Protease Plasmepsin 4, a Potential Transmission-blocking Target of the Plasmodium Ookinete
    Li, Fengwu
    Patra, Kailash P.
    Yowell, Charles A.
    Dame, John B.
    Chin, Karen
    Vinetz, Joseph M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (11) : 8076 - 8083
  • [44] Plasmodium vivax HAP2 genetic diversity and population structure from worldwide clinical samples. A potential Transmission-Blocking malaria vaccine candidate
    Saif, Ahmed
    JOURNAL OF KING SAUD UNIVERSITY SCIENCE, 2024, 36 (07)
  • [45] EFFECTS OF TRANSMISSION-BLOCKING IMMUNITY ON PLASMODIUM-VIVAX INFECTIONS IN ANOPHELES-ALBIMANUS POPULATIONS
    RAMSEY, JM
    SALINAS, E
    RODRIGUEZ, MH
    BEAUDOIN, RL
    JOURNAL OF PARASITOLOGY, 1994, 80 (01) : 88 - 92
  • [46] Salvador II strain of Plasmodium vivax in Aotus monkeys and mosquitoes for transmission-blocking vaccine trials
    Collins, WE
    Richardson, BB
    Morris, CL
    Sullivan, JS
    Galand, GG
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1998, 59 (01): : 29 - 34
  • [47] Variation in relapse frequency and the transmission potential of Plasmodium vivax malaria
    White, Michael T.
    Shirreff, George
    Karl, Stephan
    Ghani, Azra C.
    Mueller, Ivo
    PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2016, 283 (1827)
  • [48] Worldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax
    Doi, Masanori
    Tanabe, Kazuyuki
    Tachibana, Shin-Lchiro
    Hamai, Meiko
    Tachibana, Mayumi
    Mita, Toshihiro
    Yagi, Masanori
    Zeyrek, Fadile Yildiz
    Ferreira, Marcelo U.
    Ohmae, Hiroshi
    Kaneko, Akira
    Randrianarivelojosia, Milijaona
    Sattabongkot, Jetsumon
    Cao, Ya-Ming
    Horii, Toshihiro
    Torii, Motomi
    Tsuboi, Takafumi
    VACCINE, 2011, 29 (26) : 4308 - 4315
  • [49] Erratum to: Characterization of a Plasmodium berghei sexual stage antigen PbPH as a new candidate for malaria transmission-blocking vaccine
    Xu Kou
    Wenqi Zheng
    Feng Du
    Fei Liu
    Meilian Wang
    Qi Fan
    Liwang Cui
    Enjie Luo
    Yaming Cao
    Parasites & Vectors, 10
  • [50] The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials
    Ramjanee, Souraya
    Robertson, James S.
    Franke-Fayard, Blandine
    Sinha, Ria
    Waters, Andrew P.
    Janse, Chris J.
    Wu, Yimin
    Blagborough, Andrew M.
    Saul, Allan
    Sinden, Robert E.
    VACCINE, 2007, 25 (05) : 886 - 894